¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"plasma therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® interstitial therapy ÇÑ±Û ±ÙÁ¢Ä¡·á
¼³¸í   
  ÁַΠÁ¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ¿© ÀÎü Á¶Á÷³»¿¡ ¹æ»ç¼± ¹°ÁúÀ» »ðÀÔÇÏ¿© ¹æ»ç¼±À» Á¶»çÇϴ ġ·á¹ýÀÌ´Ù. Brachytherapy¶ó°íµµ ÇÑ´Ù.
¿µ¹® symptomatic therapy ÇÑ±Û ´ëÁõ¿ä¹ý
¼³¸í   
  º´ÀÇ ¿øÀÎÀ» Ã£¾Æ ¾ø¾Ö±â °ï¶õÇÑ »óȲ¿¡¼­, °ÑÀ¸·Î ³ªÅ¸³­ º´ÀÇ Áõ»ó¿¡ ´ëÀÀÇÏ¿© Ã³Ä¡¸¦ Çϴ ġ·á¹ý. ¿­ÀÌ ³ôÀ» ¶§¿¡ ¾óÀ½ÁָӴϸ¦ ´ë°Å³ª ÇØ¿­Á¦¸¦ ½á¼­ ¿­À» ³»¸®°Ô Çϴ µûÀ§°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. 
¿µ¹® radiation therapy ÇÑ±Û ¹æ»ç¼±¿ä¹ý
¼³¸í   
  X¼±, ¥ã¼±ÀÇ ÀüÀÚ¹æ»ç¼±À̳ª ÀüÀÚ¼±, ¾çÀÚ¼±, Áß¼ºÀÚ¼± µîÀÇ ÀÔÀÚ¹æ»ç¼±À» ÀÌ¿ëÇØ, ÁַΠ¾Ç¼º Á¾¾ç Ä¡·á¸¦ ¸ñÀûÀ¸·Î Çϴ ġ·á¹ýÀÌ´Ù. ¾Ï¼¼Æ÷°¡ ÁÖÀ§ÀÇ Á¤»ó¼¼Æ÷º¸´Ùµµ ¹æ»ç¼± °¨¼ö¼ºÀÌ ³ôÀº Á¡À» ÀÌ¿ëÇÏ¿©, Á¤»ó¼¼Æ÷ÀÇ ¼Õ»óÀ» °¡´ÉÇÑ ÇÑ ÃּҷΠ¾ïÁ¦Çϸ鼭 ¾Ï¼¼Æ÷¸¦ ÆÄ±«ÇÑ´Ù. »ç¿ëµÇ´Â ¹æ»ç¼±¿¡´Â ¹ÐºÀ¼Ò¼±¿ø¿¡¼­ ³ª¿À´Â ¥ã¼±, Á÷¼±°¡¼Ó±â¿¡¼­ ¾ò¾îÁö´Â °í¿¡³ÊÁö X¼±°ú ÀüÀÚ¼±, ÅÚ·¹ÄÚ¹ßÆ®ÀåÄ¡¿¡ ÀÇÇÑ 60CoÀÇ ¥ã¼±°ú, º£Å¸Æ®·Ð¿¡ ÀÇÇÑ ÀüÀÚ¼±, »çÀÌÅ©·ÎÆ®·Ð¿¡¼­ ¾ò¾îÁö´Â ¾çÀÚ¼±, Áß¼ºÀÚ¼± µîÀÌ ÀÖ´Ù. 
¿µ¹® radiation therapy ÇÑ±Û ¹æ»ç¼±Ä¡·á
¼³¸í   
  ¹æ»ç¼±ÀÇ »ì±ÕÈ¿°ú³ª ¼¼Æ÷¸¦ Á×À̴ ȿ°ú¸¦ Ä¡·á¿¡ ÀÌ¿ëÇϴ ¹æ¹ýÀ¸·Î, Á¼Àº Àǹ̷Π¾ÏÀÇ ¹æ»ç¼±Ä¡·á¸¦ ÀǹÌÇÑ´Ù. ¾Ï¿¡ ´ëÇÑ ¹æ»ç¼±Ä¡·á´Â ¾Ï¼¼Æ÷¸¦ Á×À̴µ¥ È¿°ú°¡ Å« º£Å¸¼±À» ÁַΠ»ç¿ëÇÑ´Ù. ÇÏÁö¸¸, ÀÌ·± ¹æ»ç¼±Ä¡·á´Â Á¤»ó¼¼Æ÷¿¡µµ Å« ¿µÇâÀ» ³¢ÃÄ ÀÌ¿¡ µû¸¥ ±â´ÉÀÇ Àå¾Ö¸¦ °¡Á®¿Ã ¼ö ÀÖ´Ù. µû¶ó¼­ ¹æ»ç¼±Ä¡·á¿¡ À־´Â ´ÜÁö ±× ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ÀÛ¿ë»Ó¸¸ ¾Æ´Ï¶ó, Á¤»ó¼¼Æ÷¿¡ ´ëÇÑ ÀÛ¿ëµµ °í·ÁÇÏ¿© ½ÃÇàÇÑ´Ù.
¿µ¹® speech therapy ÇÑ±Û ¾ð¾îÄ¡·á
¼³¸í   
  ¸»À» Á¤È®ÇϰԠ¹ßÀ½ÇÒ ¼ö ¾ø°Å³ª ´õµë´Â È¯ÀÚ¿¡°Ô ¹ßÀ½, ´ëÈ­ µûÀ§ÀÇ ÈÆ·ÃÀ» Àü¹®ÀûÀ¸·Î ÇàÇϴ ġ·á¹ý. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè
  • plasma exchange
    Ç÷À屳ȯ(¼ú)
  • plasma expander
    Ç÷ÀåÁõ·®Á¦
  • plasma hemoglobin
    Ç÷ÀåÇ÷»ö¼Ò
  • plasma iron
    Ç÷Àåö
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À²
  • plasma membrane
    ÇüÁú¸·
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma substitute
    Ç÷Àå´ëüÁ¦
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • plasma volume expander
    Ç÷ÀåÁõ·®Á¦
  • pooled blood plasma
    È¥ÇÕÇ÷Àå
  • seminal plasma
    Á¤¾×Àå¾×
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • home oxygen therapy
    °¡Á¤»ê¼Ò¿ä¹ý
  • initial therapy
    ÃʱâÄ¡·á
  • O2 therapy
    »ê¼Ò¿ä¹ý
  • radiation therapy
    ¹æ»ç¼±¿ä¹ý, ¹æ»ç¼±Ä¡·á
  • replacement therapy
    ´ëÄ¡¿ä¹ý
  • speech therapy
    ¾ð¾îÄ¡·á
  • supportive therapy
    ÁöÁö¿ä¹ý
  • symptomatic therapy
    ´ëÁõ¿ä¹ý
  • systemic therapy
    Àü½Å¿ä¹ý
  • thrombolytic therapy
    Ç÷Àü¿ëÇØ¿ä¹ý
  • topical therapy
    ±¹¼Ò¿ä¹ý
  • work therapy
    ÀÛ¾÷¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷À¯¹æ¿°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾
  • plasma cross matching
    (¢¡cross matching) Ç÷Àå±³Â÷½ÃÇè
  • plasma
    Ç÷Àå, ¿øÇüÁú, ¼¼Æ÷Áú
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma substitute
    Ç÷Àå´ëÄ¡Á¦
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma iron pool
    Ç÷ÀåöÀúÀå°í
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À²
  • pooled blood plasma
    È¥ÁÖÇ÷Àå
  • seminal plasma
    Á¤¾×Àå¾×
  • true plasma
    ¼øÇ÷Àå
  • stable plasma protein solution
    ¾ÈÁ¤Ç÷Àå´Ü¹é¿ë¾×
  • activity therapy
    Ȱµ¿¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antifungal therapy
    Ç×°õÆÎÀÌÄ¡·á
  • antimicrobial therapy
    Ç×±Õ¿ä¹ý(ù÷жèþÛö).
  • art therapy
    ¿¹¼ú¿ä¹ý
  • fractionated stereotactic radiation therapy
    ºÐÇÒÁ¤À§ ¹æ»ç¼±Ä¡·á
  • gold therapy
    ±Ý Ä¡·á
  • gonadotropin therapy
    ¼º¼±ÀÚ±ØÈ£¸£¸ó¿ä¹ý.
  • grenz-ray therapy
    ±×·£Â꼱ġ·á
  • health resort therapy
    ÀüÁö¿ä¹ý(ÊÙËíËÑ).
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
  • hyperbaric oxygen therapy
    °í¾Ð»ê¼Ò¿ä¹ý
  • hyperbaric oxygenation therapy
    °í¾Ð»ê¼Ò¿ä¹ý(ÍÔäâß«áÈèþÛö)
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunosuppressive therapy
    ¸é¿ª¾ïÁ¦¿ä¹ý(¡­åäð¤èþÛö).
  • immunosuppressive therapy
    ¸é¿ª¾ïÁ¦¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • liquid plasma
    ¾×»óÇ÷Àå(äûßÒúìíì).
  • lymph plasma
    ¸²ÇÁÀå¾×
  • oxalated plasma
    ¿Á»ì»ê÷°¡Ç÷Àå(?Ì´Ëö).
  • plasma
    Ç÷Àå
  • plasma
    Ç÷Àå(úìíì), ÇöóÁ.
  • plasma analysis
    Ç÷ÀåºÐ¼®
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell
    ÇüÁú(û¡òõ)¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà).
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell balanitis => balanitis circumscripta plasmacellularis
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷ÀÌȥȭÁõ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ(û¡òõá¬øàòðü´), ÇüÁú¼¼Æ÷Àå¾Ö(¡­î¡äô), ÇüÁú¼¼Æ÷ÀÌȥȭÁõ(¡­ì¶ûèûúñø)
  • plasma cell gingivostomatitis
    ÇüÁú¼¼Æ÷ Ä¡Àº ±¸³»¿°
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷ ¹éÇ÷º´
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • plasma thromboplastic factor
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ(úìíìúìîûû¡à÷ì×í­)
  • plasma thromboplastic factor B
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ B
  • plasma thromboplastin antecedent
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ Àü±¸¹°(îñÏÌÚª)
  • plasma thromboplastin component
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ¼ººÐ(à÷ÝÂ)
  • plasma transferrin
    Ç÷Àå(úìíì) Æ®¶õ½ºÆä¸°
  • plasma transglutaminase
    Ç÷Àå(úìíì) Æ®¶õ½º±Û·çŸ¹Ì³×À̽º
  • separated plasma
    ºÐ¸®Ç÷Àå(ÝÂ×îúìíì)
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • true plasma
    ¼øÇ÷Àå(âíúìíì)
  • whole plasma
    ÀüÇ÷Àå(îïúìíì)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PT pain threshold; parathormone; parathyroid; paroxysmal tachycardia; part time; patient; pericardial t...
FENa, FeNa Fractional Excretion of Sodium
  ; VolumeÀÇ °³³äÀ» Á¦°ÅÇÏ¿© Á» ´õ Á¤È®ÇÑ ½ÅÀåÀÇ ³óÃà ´É·ÂÀ» Æò°¡,
 &n...
TPC thromboplastic plasma component; thyroid papillary carcinoma; total patient care; total plasma catec...
AART American Association for Rehabilitation Therapy; American Association for Respiratory Therapy
ACT achievement through counseling and treatment; actin; actinomycin; activated clotting time; advanced ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BNCT Boron Neutron Capture Therapy
BCT Breast Conserving Therapy
BCT Breast conservation therapy
CBT Cognitive Behavioral Therapy
CBT Cognitive Behaviour Therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma substitute
    Ç÷Àå ´ë¿ëÁ¦
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pooled plasma
    È¥ÁÖ Ç÷Àå
  • renal plasma flow
    ½Å Ç÷Àå·ù, ½Å Ç÷Àå·ù·®
  • venous plasma blood glucose
    Á¤¸Æ Ç÷Àå Ç÷´çÄ¡, Á¤¸Æ Ç÷Àå Ç÷´ç
  • acrylic splint therapy
    ¾ÆÅ©¸± ¾ÈÁ¤ ±³ÇÕ»ó Ä¡·á
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
  • adaptive radiation therapy
    ÀûÀÀ ¹æ»ç¼± Ä¡·á, ¼øÀÀ ¹æ»ç¼± Ä¡·á
  • adjunctive therapy
    ºÎ°¡ ¿ä¹ý
    ÁÖµÈ Ä¡·á °úÁ¤ ÀÌ¿ÜÀÇ Ãß°¡ Ä¡·á °úÁ¤.
  • adjuvant therapy
    º¸Á¶ ¿ä¹ý
  • anticoagulant therapy
    Ç×ÀÀ°í Ä¡·á, Ç×ÀÀ°í ¿ä¹ý
  • antimicrobial therapy
    Ç×±Õ ¿ä¹ý
  • atropine therapy
    ¾ÆÆ®·ÎÇÉ Ä¡·á, ¾ÆÆ®·ÎÇÉ ¿ä¹ý
  • aversion therapy
    Çø±â¿ä¹ý
    ¿øÇÏÁö ¾Ê´Â Çൿ ÆÐÅÏÀ» ºÒÄèÇÑ Àڱذú °áºÎ½ÃŰ´Â °Í. ¶Ç´Â ¿øÇÏÁö ¾Ê´Â ÇàÀ§·ÎºÎÅÍ ºÒÄèÇÑ ÀÚ±ØÀÌ »ý±âµµ·Ï ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ Ä¡·á.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
plasma accelerator globulin <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
plasma albumin <protein> The serum level of the low molecular protein albumin. Albumin, produced by the liver, plays an important role in maintaining plasma oncotic pressure. Normal serum albumin should be 3.5-5.0 grams per decilitre. Low serum albumin can be found in cases of liver disease and malnutrition.
(27 Sep 1997)
plasma cell <haematology> A terminally differentiated antibody forming and usually antibody secreting, cell of the B-cell lineage.
(18 Nov 1997)
plasma cell balanitis Benign circumscribed balanitis characterised microscopically by subepithelial plasma cell infiltration and clinically by small erythematous papular lesions.
Synonym: balanitis circumscripta plasmacellularis, balanitis of Zoon, Zoon's erythroplasia.
(05 Mar 2000)
plasma cell dyscrasia A diverse group of diseases characterised by the proliferation of a single clone of cells producing a monoclonal immunoglobulin or immunoglobulin fragment (a serum M component). The cells usually have plasma cell morphology, but may have lymphocytic or lymphoplasmacytic morphology. This group includes multiple myeloma, Waldenstrom's macroglobulinaemia, the heavy chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis.
(05 Mar 2000)
plasma cell gingivitis Intense hyperaemic oedema and inflammation of the gingiva resulting from a hypersensitivity reaction. A dense plasma cell infiltrate is seen in the lamina propria.
Synonym: atypical gingivitis.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
plasma cell leukaemia An unusual disease characterised by leukocytosis and other signs and symptoms that are suggestive of leukaemia, in association with diffuse infiltrations and aggregates of plasma cells in the spleen, liver, bone marrow, and lymph nodes, and the presence of considerable numbers of plasma cells in the circulating blood; the total number of leukocytes in the latter may range from normal levels to 80,000 or 90,000 per cu mm, and 5 to 90% may be plasma cells; multiple myelomas are observed in some examples of plasma cell leukaemia, but discrete nodules are not formed in bone. Although there are other clinicopathologic differences in the two conditions, they may be phases of the same basic process.
(05 Mar 2000)
plasma cell mastitis A condition of the breasts characterised by tumourlike indurated masses containing numerous plasma cells, usually resulting from mammary duct ectasia; although clinically resembling malignant disease (attachment to skin and enlargement of axillary lymph nodes), it is not neoplastic.
(05 Mar 2000)
plasma cell myeloma Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma.
(05 Mar 2000)
plasma cells Special white blood cells that produce antibodies.
(12 Dec 1998)
plasma containment <physics> In physics experiments or nuclear fusion experiments, operation is intended to prevent, in an effective and sufficiently prolonged manner, the particles of a plasma from striking the walls of the container in which this plasma is produced.
Plasma confinement is a fundamental requirement for obtaining net energy from a fusion plasma. The reason is that scattering (hence diffusion) is at least an order of magnitude more probable than fusion reactions. Hence, without confinement, the plasma fuel would disperse before enough fusion reactions could take place.
(31 Dec 1997)
plasma exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (ppf), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.
(12 Dec 1998)
plasma expander Artificial plasma extender.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • group therapy
    Áý´Ü ¿ä¹ý
  • hyperbaric oxygen therapy
    °í³óµµ »ê¼Ò ¿ä¹ý(ÀÏ»êȭź¼Ò Áßµ¶,³úÁ¹Áõ,´Ù¹ß¼º °æÈ­Áõ µî¿¡ »ç¿ëµÊ)
  • milieu therapy
    (»ýȰ ȯ°æÀ» ¹Ù²Ù´Â) ȯ°æ ¿ä¹ý
  • needle therapy
    ħ¿ä¹ý;ħ¼ú(acupuncture)
  • occupational therapy
    ÀÛ¾÷¿ä¹ý
  • primal scream therapy
    ÇÁ¶óÀÌ¸Ö ½ºÅ©¸² ¿ä¹ý(À¯¾Æ±âÀÇ ¿Ü»ó üÇèÀ» ÀçüÇè½ÃÄÑ ½Å°æÁõÀ» Ä¡·áÇÏ´Â Á¤½Å ¿ä¹ý)
  • pulse therapy
    ÆÞ½º (Ãæ°Ý) ¿ä¹ý
  • radium therapy
    ¶óµã ¿ä¹ý
  • reality therapy
    Çö½Ç ¿ä¹ý(ȯÀÚ°¡ óÇÑ Çö½ÇÀ» ÀνÄÄÉÇÏ¿© Çö½Ç¿¡ ÀûÀÀÅä·Ï ÇÏ´Â ½É¸® ¿ä¹ý)
  • reinforcement therapy
    ´Ù½Ã À×Å©¸¦ ¹¯È÷´Ù
  • shock therapy
    (Á¤½Åº´ÀÇ)Ãæ°Ý(Àü°Ý)¿ä¹ý
  • speech therapy
    ¾ð¾îÀå¾Ö ±³Á¤(¼ú) 
  • therapy
    Ä¡·á
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á